Local tumor removal plus chemo-radiation for early low rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether removing just the tumor locally, followed by chemotherapy and radiation, is effective for early-stage (T1-2 N0) rectal cancers located low or very low in the rectum. It may help you keep your anal opening and avoid major surgery that requires a permanent colostomy bag.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your tumor is a type of rectal cancer called adenocarcinoma and is at an early stage (still in the first layer, not spread to lymph nodes or other organs)
- The bottom edge of your tumor is no more than 2 inches (about 8 cm) from the anal opening
- You are healthy enough for daily activities (ECOG score of 0 or 1)
- You strongly want to avoid surgery that removes the anus, and your surgeon says it's safe to remove just the tumor
- You are willing to have chemotherapy and radiation after the surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches for a small, early-stage rectal cancer (T1N0). Some people get chemoradiotherapy before the tumor is removed, while others go straight to surgery. The goal is to see if adding chemoradiotherapy lowers the chance of the cancer coming back.
This trial studies removing an early rectal cancer tumor locally (through the rectum/anal area) with no additional therapy afterward. The goal is to preserve organs and maintain quality of life while still trying to cure the cancer.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a combination of radiation therapy, chemotherapy, and two immunotherapy drugs (which help your immune system fight cancer) as a way to treat early-stage rectal cancer that is low in the rectum. The goal is to see if this approach can shrink or eliminate the cancer so that surgery might be avoided.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
Hear when a new Rectal Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.